REAl-world outcomes in CHronic lymphocytic leukemia patients receiving acalabrutinib in Romania

Trial Identifier: D8220R00055
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: September 2028
Study Completion Date: September 2028
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Romania, Arges Pitesti, Arges, Romania, 110084
Romania, Bihor Oradea, Bihor, Romania, 410469
Romania, Brasov Brasov, Romania, 500052
Romania, Bucuresti Bucuresti, Romania, 20125
Romania, Bucuresti Bucuresti, Romania, 30171
Romania, Bucuresti Bucuresti, Romania, 50098
Romania, Bucuresti Bucuresti, Romania, 22328
Romania, Bucuresti Bucuresti, Romania, 301710
Romania, Cluj Cluj Napoca, Cluj, Romania, 400015
Romania, Dolj Craiova, Dolj, Romania, 200143
Romania, Galati Galati, Romania, 800578
Romania, Hunedoara Deva, Hunedoara, Romania, 330084
Romania, Iasi Iasi, Romania, 700483
Romania, Maramures Baia Mare, Maramures, Romania, 430031
Romania, Mures Targu Mures, Mures, Romania, 540136
Romania, Neamt Piatra Neamt, Neamt, Romania, 610136
Romania, Timis Timisoara, Timis, Romania, 300254
Romania, Timis Timisoara, Timis, Romania, 300239
Romania, Vrancea Focsani, Vrancea, Romania, 620034